Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 369-378

  Nam, Sangkil ^a   Wen, Wei ^a   Schroeder, Anne ^a   Herrmann, Andreas ^a   Yu, Hua ^a   Cheng, Xinlai ^b   Merz, Karl Heinz ^b   Eisenbrand, Gerhard ^b   Li, Hongzhi ^a   Yuan, Yate Ching ^a   Jove, Richard ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b France   (Germany)

Author keywords

AAD; Apoptosis; Indirubin derivative (IRD); IRD; JAK; JAKs; MD; SFK; SFKs; STAT; Stat3; Tyk2

Indexed keywords

HEMATOPOIETIC CELL KINASE; INDIRUBIN; JANUS KINASE; PROTEIN KINASE TYK2; PROTEIN MCL 1; STAT3 PROTEIN; SURVIVIN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DYNAMICS; NUCLEOTIDE BINDING SITE; ONCOGENE SRC; PANCREAS CANCER; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 84878116135     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.10.013     Document Type: Article

References (36)

1. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
3. Cheng X., Rasque P., Vatter S., Merz K.H., Eisenbrand G. Synthesis and cytotoxicity of novel indirubin-5-carboxamides. Bioorg. Med. Chem. 2010, 18:4509-4515.
4. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
5. Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., Firpo M.A., Mulvihill S.J. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010, 39:425-435.
6. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47:1739-1749.
7. Friesner R.A., Murphy R.B., Repasky M.P., Frye L.L., Greenwood J.R., Halgren T.A., Sanschagrin P.C., Mainz D.T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49:6177-6196.
8. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A., Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20:2499-2513.
9. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z.A., Yu H., Jove R., Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
10. Hennequin L.F., Allen J., Breed J., Curwen J., Fennell M., Green T.P., Lambert-van der Brempt C., Morgentin R., Norman R.A., Olivier A., Otterbein L., Ple P.A., Warin N., Costello G. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 2006, 49:6465-6488.
11. Herrmann A., Sommer U., Pranada A.L., Giese B., Kuster A., Haan S., Becker W., Heinrich P.C., Muller-Newen G. STAT3 is enriched in nuclear bodies. J. Cell. Sci. 2004, 117:339-349.
12. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell. Biol. 1999, 1:60-67.
13. Humphrey W., Dalke A., Schulten K. VMD: visual molecular dynamics. J. Mol. Graph. 1996, 14(33-38):27-38.
14. Johnson F.M., Saigal B., Tran H., Donato N.J. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin. Cancer Res. 2007, 13:4233-4244.
15. Kim L.C., Song L., Haura E.B. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009, 6:587-595.
16. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:1779-1790.
17. Levine R.L., Gilliland D.G. Myeloproliferative disorders. Blood 2008, 112:2190-2198.
18. Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2:358-364.
19. Luo C., Laaja P. Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov. Today 2004, 9:268-275.
20. Marko D., Schatzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., Eisenbrand G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer 2001, 84:283-289.
21. Nagaraj N.S., Smith J.J., Revetta F., Washington M.K., Merchant N.B. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol. Cancer Ther. 2010, 9:2322-2332.
22. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., Hippe F., Vatter S., Merz K.H., Eisenbrand G., Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. U S A 2005, 102:5998-6003.
23. O'Shea J.J., Gadina M., Schreiber R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002, 109(Suppl):S121-S131.
24. O'Shea J.J., Pesu M., Borie D.C., Changelian P.S. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 2004, 3:555-564.
25. Parsons S.J., Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 2004, 23:7906-7909.
26. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., Chipot C., Skeel R.D., Kale L., Schulten K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26:1781-1802.
27. Raimondi S., Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an overview. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:699-708.
28. Rane S.G., Reddy E.P. Janus kinases: components of multiple signaling pathways. Oncogene 2000, 19:5662-5679.
29. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zahurak M., Goodman S.N., Sohn T.A., Hruban R.H., Yeo C.J., Kern S.E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997, 57:1731-1734.
30. Sen B., Saigal B., Parikh N., Gallick G., Johnson F.M. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 2009, 69:1958-1965.
31. Tsui V., Gibbons P., Ultsch M., Mortara K., Chang C., Blair W., Pulk R., Stanley M., Starovasnik M., Williams D., Lamers M., Leonard P., Magnuson S., Liang J., Eigenbrot C. A new regulatory switch in a JAK protein kinase. Proteins 2011, 79:393-401.
32. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
33. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 2004, 4:470-480.
34. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
35. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
36. Zhang Y., Turkson J., Carter-Su C., Smithgall T., Levitzki A., Kraker A., Krolewski J.J., Medveczky P., Jove R. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J. Biol. Chem. 2000, 275:24935-24944.